[1] Faux J, Venisse N, Olivie PJ,et al. Rapid high-performance liquid chromatography determination of lopinavir, a novel HIV-1 protease inhibitor, in human plasma[J]. Chromatographia, 2001, 54:469.
[2] Jaspervander L,Anchalee A.clinical pharmacology and pharmacokinetics of antiretrovirals in Asia[J]. Asian Biomedicine,2009,3(1):53.
[3] Eric D,Veronique R, Francois R, et al. A population approach to study the influence of nevirapine administration on lopinavir pharmacokinetics in HIV-1 infected patients[J]. Eur J Clin Pharmacol,2005,61:153.
[4] Matthias G, Stephanie R, Stephanie L,et al. Pharmacogenomic adaptation of antiretroviral therapy:overcoming the failure of lopinavir in an African infant with CYP2D6 ultrarapid metabolism[J]. Eur J Clin Pharmacol,2010,66:107.
[5] Rajasekhar D, Jaswanthumar I, Ravik, et al. Simultaneous determination of ritonavir and lopinavir in human plasma after protein precipitation and LC-MS-MS[J]. Chromatographia, 2010, 71:815.
[6] Difrancesco R, Dicenzo R, Vicente G, et al. Determination of lopinavir cerebral spinal fluid and plasma ultrafiltrate concentrations by liquid chromatography coupled to tandem mass spectrometry[J]. J Pharm Biomed Anal, 2007, 44 (5):1139.
[7] Frerichs VA, Difrancesco R, Morse GD. Determination of protease inhibitors using liquid chromatography-tandem mass spectrometry[J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2003, 787(2):393.
[8] Perry GW, Jack SW, Grace K, et al. Validation and application of a high-performance liquid chromatography-tandem mass spectrometric method for simultaneous quantification of lopinavir and ritonavir in human plasma usingsemi-automated 96-well liquid-liquid extraction[J]. J Chromatogr A, 2006,1130:302.
[9] Yoshiko USAMI, Tsuyoshi OKI, Masahiko NAKAI, et al.A simple HPLC method for simultaneous determination of lopinavir,ritonavir and efavirenz[J]. Chem Pharm Bull,2003, 51(6):715.
[10] Rita CEE, Fabio SR, Brayan VS, et al.Determination of lopinavir and ritonavir in blood plasma, seminal plasma, saliva and plasmaultra-filtrate by liquid chromatography/tandem mass spectrometry detection[J]. Rapid Commun Mass Spectrom,2008,22:657.
[11] Manuela E, Marion M, Walter EH, et al. Monitoring of lopinavir and ritonavir in peripheral blood mononuclear cells, plasma, and ultrafiltrate using a selective and highly sensitive LC/MS/MS assay[J]. J Chromatogr B, 2007, 850:249.
[12] Manish Y, Rajasekhar R, Hemal K,et al. Application of a rapid and selective method for the simultaneous determination of protease inhibitors, lopinavir and ritonavir in human plasma by UPLC-ESI-MS/MS for bioequivalence study in Indian subjects[J]. J Pharmaceut Biomed,2009, 49:1115.
[13] Heinea R,Rosinga H,Gorpb ECM,et al.Quantification of protease inhibitors and non-nucleoside reverse transcriptase inhibitors in dried blood spots by liquid chromatography-triple quadrupole mass spectrometry[J]. J Chromatogr B,2008,867:208.
[14] Yao Y,Sun J,Chen J,et al.LC-MS/MS method for simultaneous quantification of lopinavir and ritonavir in human plasma[J]. Acta Pharmaceut Sin,2010, 45 (2):279.
[15] Slish JC,Catnzaro LM, Ma Q,et al. Update on the pharmacokinetic aspects of antiretroviral agents:implications in therapeutic drug monitoring[J]. Current Pharmaceutical Design, 2006, 12:1129.
[16] Van Heeswijk RPG, Bourbeau M, Seguin I, et al. Absence of circadian variation in the pharmacokinetics of lopinavir/ritonavir given as a once daily dosing regimen in HIV-1-infected patients[J]. Br J Clin Pharmacol, 2005, 59 (4):398.
[17] Gondi NK, Venkata KJ, Marianne KJ,et al. Metabolism and disposition of the HIV-1 protease inhibitor lopinavir (ABT-378) given in combination with ritonavir in rats, dogs, and humans[J]. Pharmacol Res, 2004, 21(9):1622.
[18] Jackson A, Hill A, Puls R,et al.Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers[J]. J Antimicro Chemoth,2011,66(3):635.
[19] Ann H, Jeffrey I, Scott B. Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients[J]. Antimicrob Agents Ch,2003, 47(1):350.
[20] Natella R, John A, Aline B, et al.Population pharmacokinetics of lopinavir predict suboptimal therapeutic concentrations in treatment-experienced human immunodeficiency virus-infected children[J]. Antimicrob Agents Ch,2009, 53(6):2532.